First Trust Advisors LP reduced its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 84.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,085 shares of the company’s stock after selling 27,452 shares during the quarter. First Trust Advisors LP’s holdings in Omnicell were worth $267,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMCL. Penn Capital Management Co. Inc. bought a new stake in Omnicell during the first quarter worth $9,400,000. Pwmco LLC bought a new stake in Omnicell during the second quarter worth $8,141,000. Westwood Holdings Group Inc. raised its position in Omnicell by 23.0% during the first quarter. Westwood Holdings Group Inc. now owns 650,078 shares of the company’s stock worth $28,213,000 after acquiring an additional 121,460 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new stake in Omnicell during the second quarter worth $5,789,000. Finally, New York State Common Retirement Fund raised its position in Omnicell by 261.1% during the first quarter. New York State Common Retirement Fund now owns 142,983 shares of the company’s stock worth $6,205,000 after acquiring an additional 103,383 shares in the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

In other Omnicell news, insider Peter J. Kuipers sold 2,818 shares of the company’s stock in a transaction on Monday, July 16th. The shares were sold at an average price of $53.06, for a total value of $149,523.08. Following the transaction, the insider now directly owns 54,370 shares in the company, valued at $2,884,872.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Nhat H. Ngo sold 20,436 shares of the company’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $55.00, for a total transaction of $1,123,980.00. Following the completion of the transaction, the executive vice president now owns 57,750 shares in the company, valued at $3,176,250. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,064 shares of company stock worth $3,946,985. Corporate insiders own 3.71% of the company’s stock.

Several analysts have issued reports on OMCL shares. BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 9th. Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Friday, July 27th. TheStreet raised shares of Omnicell from a “c+” rating to a “b” rating in a research report on Friday, July 27th. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Thursday, August 2nd. Finally, ValuEngine raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $63.20.

NASDAQ:OMCL opened at $70.20 on Wednesday. Omnicell, Inc. has a one year low of $39.75 and a one year high of $73.00. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 390.00, a P/E/G ratio of 3.46 and a beta of 1.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.27 and a current ratio of 1.78.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 26th. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.07. Omnicell had a net margin of 5.27% and a return on equity of 5.88%. The firm had revenue of $188.70 million for the quarter, compared to the consensus estimate of $188.80 million. During the same period in the previous year, the company earned $0.31 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. analysts predict that Omnicell, Inc. will post 1.35 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: What is the NASDAQ?

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.